CN102702001B - 稳定的无定型盐酸氨溴索化合物 - Google Patents
稳定的无定型盐酸氨溴索化合物 Download PDFInfo
- Publication number
- CN102702001B CN102702001B CN 201210231927 CN201210231927A CN102702001B CN 102702001 B CN102702001 B CN 102702001B CN 201210231927 CN201210231927 CN 201210231927 CN 201210231927 A CN201210231927 A CN 201210231927A CN 102702001 B CN102702001 B CN 102702001B
- Authority
- CN
- China
- Prior art keywords
- ambroxol hcl
- unformed
- ambroxol
- recipe quantity
- ambroxol hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 ambroxol hydrochloride compound Chemical class 0.000 title claims abstract description 21
- 229960000985 ambroxol hydrochloride Drugs 0.000 title abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 238000010521 absorption reaction Methods 0.000 claims abstract description 4
- 229960005174 ambroxol Drugs 0.000 claims description 87
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 claims description 78
- 238000000034 method Methods 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 12
- 239000008215 water for injection Substances 0.000 claims description 10
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 claims description 9
- 229960000583 acetic acid Drugs 0.000 claims description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 239000012362 glacial acetic acid Substances 0.000 claims description 8
- 238000007689 inspection Methods 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000001291 vacuum drying Methods 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 5
- 239000003610 charcoal Substances 0.000 claims description 5
- 229940105082 medicinal charcoal Drugs 0.000 claims description 5
- 239000001632 sodium acetate Substances 0.000 claims description 5
- 229960004249 sodium acetate Drugs 0.000 claims description 5
- 235000017281 sodium acetate Nutrition 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000000967 suction filtration Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 abstract description 16
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 14
- 208000026435 phlegm Diseases 0.000 abstract description 14
- 239000000126 substance Substances 0.000 abstract description 13
- 206010006451 bronchitis Diseases 0.000 abstract description 11
- 210000003802 sputum Anatomy 0.000 abstract description 11
- 208000024794 sputum Diseases 0.000 abstract description 11
- 238000011282 treatment Methods 0.000 abstract description 11
- 208000006673 asthma Diseases 0.000 abstract description 9
- 238000004090 dissolution Methods 0.000 abstract description 7
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 abstract description 6
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 abstract description 6
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 abstract description 6
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract description 5
- 208000019693 Lung disease Diseases 0.000 abstract description 4
- 230000001154 acute effect Effects 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 230000001684 chronic effect Effects 0.000 abstract description 3
- 230000002028 premature Effects 0.000 abstract description 3
- 238000011321 prophylaxis Methods 0.000 abstract description 3
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 abstract description 2
- 210000004072 lung Anatomy 0.000 abstract description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 229920002785 Croscarmellose sodium Polymers 0.000 description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 12
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 12
- 229960001681 croscarmellose sodium Drugs 0.000 description 12
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 12
- 239000008101 lactose Substances 0.000 description 12
- 229940016286 microcrystalline cellulose Drugs 0.000 description 12
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 12
- 239000008108 microcrystalline cellulose Substances 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 11
- 206010011224 Cough Diseases 0.000 description 10
- 229960001375 lactose Drugs 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 210000002345 respiratory system Anatomy 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000003097 mucus Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000003908 quality control method Methods 0.000 description 6
- 239000011122 softwood Substances 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 description 5
- 206010006458 Bronchitis chronic Diseases 0.000 description 5
- 208000007451 chronic bronchitis Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000004907 gland Anatomy 0.000 description 5
- 238000005286 illumination Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 4
- 108010011485 Aspartame Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229960003438 aspartame Drugs 0.000 description 4
- 239000000605 aspartame Substances 0.000 description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 4
- 235000010357 aspartame Nutrition 0.000 description 4
- 229960001305 cysteine hydrochloride Drugs 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- IMLXLGZJLAOKJN-UHFFFAOYSA-N 4-aminocyclohexan-1-ol Chemical compound NC1CCC(O)CC1 IMLXLGZJLAOKJN-UHFFFAOYSA-N 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 230000002924 anti-infective effect Effects 0.000 description 3
- 229960005475 antiinfective agent Drugs 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 210000002175 goblet cell Anatomy 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical compound Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 2
- 230000009798 acute exacerbation Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 2
- 229960003321 baicalin Drugs 0.000 description 2
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 201000009267 bronchiectasis Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004081 cilia Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000009325 pulmonary function Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000001533 respiratory mucosa Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- RCPAZWISSAVDEA-UHFFFAOYSA-N 2-amino-3,5-dibromobenzaldehyde Chemical compound NC1=C(Br)C=C(Br)C=C1C=O RCPAZWISSAVDEA-UHFFFAOYSA-N 0.000 description 1
- JBDGDEWWOUBZPM-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]-1-cyclohexanol Chemical compound NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 JBDGDEWWOUBZPM-UHFFFAOYSA-N 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- 229910016523 CuKa Inorganic materials 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 210000000254 ciliated cell Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 238000006704 dehydrohalogenation reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- KYEPHZAHIRDQSR-SXASYTFBSA-L potassium;sodium;4-[[(1r,2r,4ar,5r,8as)-2-(3-carboxylatopropanoyloxy)-1,4a-dimethyl-6-methylidene-5-[(e)-2-(5-oxo-2h-furan-4-yl)ethenyl]-3,4,5,7,8,8a-hexahydro-2h-naphthalen-1-yl]methoxy]-4-oxobutanoate Chemical compound [Na+].[K+].C(/[C@@H]1C(=C)CC[C@H]2[C@@]1(C)CC[C@H]([C@]2(COC(=O)CCC([O-])=O)C)OC(=O)CCC([O-])=O)=C\C1=CCOC1=O KYEPHZAHIRDQSR-SXASYTFBSA-L 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000002385 vertebral artery Anatomy 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
测定条件时间 | 含量(%) | 杂质B | 杂质E(%) | 其它总杂质(%) | 外观 |
光照0天 | 99.95 | 0.009 | 0.001 | 0.010 | 白色粉末 |
光照5天 | 99.94 | 0.011 | 0.001 | 0.010 | 白色粉末 |
光照10天 | 99.94 | 0.013 | 0.001 | 0.011 | 白色粉末 |
高温0天 | 99.95 | 0.009 | 0.001 | 0.010 | 白色粉末 |
高温5天 | 99.93 | 0.010 | 0.001 | 0.011 | 白色粉末 |
高温10天 | 99.93 | 0.012 | 0.001 | 0.012 | 白色粉末 |
高湿0天 | 99.95 | 0.009 | 0.001 | 0.010 | 白色粉末 |
高湿5天 | 99.93 | 0.010 | 0.001 | 0.011 | 白色粉末 |
高湿10天 | 99.92 | 0.012 | 0.001 | 0.013 | 白色粉末 |
压力(kg) | NO.1 | NO.2 | NO.3 | 均值 |
600 | 7.8 | 7.7 | 7.9 | 7.8 |
800 | 8.2 | 8.1 | 8.2 | 8.2 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210231927 CN102702001B (zh) | 2012-07-06 | 2012-07-06 | 稳定的无定型盐酸氨溴索化合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210231927 CN102702001B (zh) | 2012-07-06 | 2012-07-06 | 稳定的无定型盐酸氨溴索化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102702001A CN102702001A (zh) | 2012-10-03 |
CN102702001B true CN102702001B (zh) | 2013-08-07 |
Family
ID=46895126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201210231927 Active CN102702001B (zh) | 2012-07-06 | 2012-07-06 | 稳定的无定型盐酸氨溴索化合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102702001B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103864628B (zh) * | 2014-02-28 | 2015-09-23 | 悦康药业集团有限公司 | 一种盐酸氨溴索化合物及口腔崩解片 |
CN106242982A (zh) * | 2015-05-15 | 2016-12-21 | 苗怡文 | 一种制备治疗呼吸系统疾病的盐酸氨溴索化合物晶体的方法 |
CN104860832B (zh) * | 2015-05-15 | 2016-08-24 | 烟台市华文欣欣医药科技有限公司 | 一种治疗呼吸系统疾病的药物盐酸氨溴索组合物 |
CN104958317A (zh) * | 2015-07-30 | 2015-10-07 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种祛痰药物盐酸氨溴索组合物 |
EP3415143A1 (en) * | 2017-06-16 | 2018-12-19 | Kai-Uwe Kern | Bromhexine for the treatment of pain |
CN107362134A (zh) * | 2017-07-23 | 2017-11-21 | 南京正宽医药科技有限公司 | 一种盐酸氨溴索口服溶液及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100548286C (zh) * | 2005-12-24 | 2009-10-14 | 石药集团中奇制药技术(石家庄)有限公司 | 一种盐酸氨溴索固体分散体及其组合物 |
-
2012
- 2012-07-06 CN CN 201210231927 patent/CN102702001B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN102702001A (zh) | 2012-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102702001B (zh) | 稳定的无定型盐酸氨溴索化合物 | |
JP5671560B2 (ja) | 固体投与形中のテトラサイクリン金属錯体 | |
JP6713001B2 (ja) | シリビン、ve、及びl−カルニチンを含有する薬物組成物 | |
CN102286045B (zh) | 罗红霉素一水合物结晶、其制备方法及含该结晶和盐酸氨溴索组合的组合物干混悬剂 | |
CN113546089B (zh) | 1-乙基-3,7-二甲基黄嘌呤在制备治疗肺炎药物中的应用 | |
CN1303065C (zh) | 氨溴索半胱氨酸类似物盐及其制备方法和用途 | |
CN104829467A (zh) | 盐酸氨溴索二水化合物 | |
CN107365272A (zh) | 一种新型咪唑类化合物及其制备方法和在医学上的应用 | |
CN101982174A (zh) | 一种镇咳平喘复方药物制剂的组方及其制备方法 | |
CN109232297A (zh) | 芬乐胺晶b型、制备方法和其组合物与用途 | |
CN102002077A (zh) | 一种唾液酸-蛋氨酸锌新型偶联物、制备工艺及其应用 | |
CN103772355B (zh) | 雷贝拉唑钠化合物 | |
CN103626722B (zh) | 一氧化氮供体型降血糖化合物、其制备方法和用途 | |
CN110215510B (zh) | 聚普瑞锌在制备治疗或减轻放化疗所致消化道损伤药物中的应用 | |
CN104109128A (zh) | 卡博替尼苹果酸盐及其制备方法 | |
CN101781192B (zh) | 索法酮的晶型ⅵ及其制备方法和用途 | |
JP2016520538A (ja) | 鉄欠乏症および鉄欠乏性貧血の治療および予防のためのFe(III)錯体 | |
CN101735040B (zh) | 索法酮的晶型ⅲ及其制备方法和用途 | |
CN101735038B (zh) | 索法酮的晶型ⅰ及其制备方法和用途 | |
CN101735039B (zh) | 索法酮的晶型ⅱ及其制备方法和用途 | |
CN102690264B (zh) | 2-苯基-3-取代咪唑并[1,2-a]吡啶类衍生物及其制备方法 | |
CN101817741B (zh) | 索法酮的晶型ⅸ及其制备方法和用途 | |
CN101817742B (zh) | 索法酮的晶型ⅹ及其制备方法和用途 | |
CN101781193B (zh) | 索法酮的晶型ⅳ及其制备方法和用途 | |
CN102875472B (zh) | 一种硝酸益康唑化合物晶体、其制备方法及其药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20121003 Assignee: Pharmaceutical Co., Ltd. Tianjin Jin Yao Assignor: Tianjin Plum Medicine Co.,Ltd. Contract record no.: 2014120000041 Denomination of invention: Stable amorphous ambroxol hydrochloride compound Granted publication date: 20130807 License type: Common License Record date: 20140702 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Pharmaceutical Co., Ltd. Tianjin Jin Yao Assignor: Tianjin Plum Medicine Co.,Ltd. Contract record no.: 2014120000041 Date of cancellation: 20170420 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170515 Address after: 300462 West Binhai New Area of Tianjin Tianjin Development Zone No. 117 105 st Patentee after: TIANJIN MEIHUA BIOLOGICAL PHARMACEUTICAL CO., LTD. Address before: Rong Yuan Road 300384 Tianjin city Nankai District Huayuan Industrial Park No. 9 Patentee before: Tianjin Plum Medicine Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20121003 Assignee: Pharmaceutical Co., Ltd. Tianjin Jin Yao Assignor: TIANJIN MEIHUA BIOLOGICAL PHARMACEUTICAL CO., LTD. Contract record no.: 2017120000037 Denomination of invention: Stable amorphous ambroxol hydrochloride compound Granted publication date: 20130807 License type: Common License Record date: 20170526 |
|
EE01 | Entry into force of recordation of patent licensing contract |